Background: Nearly 16% of people with breast cancer (BC) have Diabetes Mellitus type 2 (DM2) and are at a higher risk of death worldwide. However, their common regulatory factors and functional mechanisms have not been profoundly understood. In this study, we used in silico approaches to study their co-regulated differentially expressed genes (DEGs) in order to explore and introduce novel therapeutic targets.
bioavailability of oxygen for effective ATP production via oxidative phosphorylation, cancer cells initiate less-productive glycolysis to produce their required energy fuel. Glycolysis does not produce enough ATP but the cell experiences up-regulation of genes responsible for absorbing more glucose known as metabolic reprogramming (6, 7) . Metabolic reprogramming plays critical roles particularly in adaptation of cancer cells to restrictive conditions dictated by tumor microenvironment. The Warburg effect is triggered by up-regulation of molecules such as GLUT proteins that promote glucose transfer across cell membrane and accumulation of cytosolic glucose (8).
Metformin (N',N'-dimethyl biguanide hydrochloride; MTFN) and curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; CURC) both have inhibitory effects on DM2 and BC, a criterion needed for our study. As an anti-DM2 drug, MTFN suppresses hyperinsulinemia and hyperglycemia by counteracting insulin resistance in DM2. MTFN inhibits gluconeogenesis and so glucose absorption from the small intestine and increases glucose uptake in the cells and reduces plasma free fatty acid concentration (9) . MTFN also increases insulin induced translocation of glucose transporters to the cell membrane and so reduces insulin resistance (8).
The anti-mitogenic effects of MTFN on cancer cells are exerted either by activating intracellular energy sensor adenosine monophosphate-activated protein kinase (AMPK) or via AMPKindependent signaling pathways (10). Major impacts of MTFN on cancer include sensitization of resistant tumors to chemo-radio-and antibody-therapy (11) (12) (13) which are mainly caused by selective killing of tumor-initiating cells or cancer stem cells (CSCs) by MTFN (14) . Such resensitizing potential of MTFN has been shown to improve the prognosis of diabetic patients who carry HER2+ BC tumors (15) . Combined with cancer drugs such as cisplatin or doxorubicin, MTFN indeed enhances their cytotoxicity and such combination synergistically reduces tumor size (16), an unexplored potential of MTFN that is being examined in clinical trials (17) .
Curcumin (CURC) induces cancer cell death by a long list of inhibitory and inducing activities on cellular pathways involved in apoptosis, autophagy and growth inhibition (18) . Reduced cell growth, arrested cell cycle and diminished tumor size and inhibited metastasis are effects of CURC on HER2+ BC xenografts (19) . Our own study indicates that CURC can synergize with TZMB as well as with anti-oxidant enzyme glutathione peroxidase-1 in inducing apoptosis in HER2-overexpressing BC cells, indicating CURC potential to challenge TZMB (20) . Together, MTFN and CURC appear to have converging points to synergize in halting tumorigenicity as a whole but also each can affect specific molecules or pathways within cancer cells. Co-treatment with MTFN and CURC indeed inhibits cancer growth, metastasis, and angiogenesis in vitro and in vivo (23), and inhibits angiogenesis, modulates immune system and induces apoptosis independent from p53 in BC (24) .
The aim of our current study is to explore fortifying effects of MTFN and CURC on inhibiting the redundant processes achievable by in silico studies. We initially identified targetable elements for both BC and DM2 by analyzing their inter-network correlations based on which inhibiting treatments can be adapted to control redundant joint processes. Our next step was to adjust MTFN/CURC co-effects on Phosphatase and tensin homolog (PTEN) which is downregulated upon MTFN treatment. PTEN is a tumor suppressor gene that antagonizes the PI3K/Akt/mTOR (25, 26) . If occurs, up-regulation of PTEN expression could be another anti-cancer dimension of MTFN/CURC co-treatment and diminishing their high-dose usage in single treatments.
METHODS

Microarray Analysis and Network Construction
Two high quality microarray datasets of human BC and DM2 were selected from the NCBI Gene Expression Omnibus (GEO): GSE65194 for BC (has various subtypes of BC: triple negative (TN), luminal A, luminal B and Her 2 + ) and GSE95849 for DM2 (for datasets information refer to Additional file 1) (27) (28) (29) (30) . The differentially expressed genes (DEGs) were identified by applying RMA algorithm in R Studio v1.1.442. The genes with adj.p.val less than 0.05 and logFC > 1 or logFC < 1 were considered as DEGs. The co-regulated DEGs were obtained through logFC screening upon joint DEGs between BC and DM2.
The co-regulated DEGs were subjected to STRING database (31) to form the protein-protein (PPI) network. The cut-off of 0.7 applied and text mining was excluded as the reliable source to get the proper amount of interactions between proteins. The resulted network was imported in Cytoscape 3.6.0 and the NetworkAnalyzer tool was used to characterize its topological features.
The Degree parameter was used as the connectivity index which considers the genes' neighbors to identify the hubs.
Mining Regulatory Factors and Performing Enrichment Analysis
The hubs were subjected to CyTargetLinker plugin (32) of Cytoscape 3.6.0 and TF2DNA server (33) (Kulakovskiy 2013, Jolma 2013, Weirauch 2014, and Mathelier 2014 were selected as curated sources) to introduce the related miRNAs and TFs respectively. The introduced miRNAs were filtered by curated miRNAs of diabetes and BC available in miR2Disease database (34).
The TFs were also filtered by obtained DEGs of BC and DM2 in the current study.
To understand the biological meaning behind the co-regulated DEGs, we performed KEGG pathway and Gene Ontology (GO) analysis using DAVID 6.7 server (35). The output was divided into three charts named Molecular Function (MF), Biological Processes (BP) and
Cellular Compartment (CC). The GO Terms were then filtered by p value less than 0.05 and the most significant GO terms were selected to be introduced. In parallel, by examining the BP list, we subjected important processes to our subsequent experiments in vitro.
Cell Culture
Human BC cell lines MCF7 (Michigan Cancer Foundation-7) and MDA-MB-231 (Michigan Cancer Foundation-7) were cultured in Dulbecco's modified eagle's medium (DMEM) plus 10% fetal calf serum (FBS), 100 U/mL penicillin, and 100 μ g/mL streptomycin and incubated at 37 C, 5 % CO2. MTFN and CURC were both purchased from Sigma-Aldrich and dissolved in DMSO to form treatment stocks.
MTT Viability Assay
The assay was carried out as we have reported (36). Serial concentrations of MTFN ranging from 5 to 21 mM and of CURC in the range of 5-21 µM were applied and DMSO as their solvent and positive control was used in parallel. The treated cells were incubated for 24 hours before incubating with the MTT solution in shaker for 30 min and reading by an ELISA reader at 580 nm wavelength. The calculated IC50 represents the treatment concentration that inhibits the growth of 50% of cells versus control cells.
Measurement of Synergism and Antagonism
We used Minitab 16 Statistical Software as a tool to design the contribution of each drug in combination. The Response Surface was used as the experiment design type. As we had two drugs (two factors), the central composites made 13 ways of co-treatment. To determine lower and higher dose of each drug, we chose axial point level to exactly draw the experiments between these concentrations. To gain more specific doses, doses of single treatments were applied and the range was narrowed to 9-13 mM for MTFN and 5-6 μ M for CURC. We then calculated combination index (CI) for the two compounds using formula below and as we have described (20):
where Dx 1 and Dx 2 represent the doses of MTFN and CURC alone needed to produce x percentage effect, and D 1 and D 2 indicate the doses of MTFN and CURC in combination required to produce this effect.
Acridine Orange/Ethidium Bromide (AO/EB) Co-staining
Cells were co-stained according to our previous reports (37). We applied the IC 50 of MTFN, CURC and of their combination as inhibitory treatments. The images of stained cells were captured using fluorescent microscope.
Flow Cytometry Evaluation of Cell Death by Annexin V-FITC/PI Double Labeling
MCF7 cells were seeded 2 × 10 5 per well in a 6 well plate. After treatments, the cells were trypsinized, were resuspended and were incubated with the stains for 5 min at room temperature before being analyzed by a FACSCalibur at 488 nm wavelength. A total of 10,000 cells were used per sample and the data were analyzed in FlowJo 7.6.1.
Reverse Transcription (RT) PCR
RT-PCR analysis was carried out as previously described (36). The primer pairs used for GAPDH as control, BAX, BCL2, and PTEN are as follows: GAPDH: 5'-CCCCCAATGTATCCGTTGTG-3' and 5'-TAGCCCAGGATGCCCTTTAGT-3' (Accession: NG_007073); BAX: 5'-TGG AGCTGCAGAGGATGATTG-3' and 5'-GAAGTTGCCGTCAGAAAACATG-3' (Accession: NG_012191); BCL2: 5'-CTGCACCTGACGCCCTTCACC-3' and 5'-CACATGACCCCACCGAACTCAAAGA-3'
(Accession: NG_009361), and PTEN: 5'-CGAACTGGTGTAATGATATGT-3' and 5'-CATGAACTTGTCTTCCCGT -3' (Accession: NG_007466). The reaction products were then visualized using Gel Electrophoresis and quantified using ImageJ1.51 software (38).
Wound Healing/ Scratch Assay
One day after seeding 3 × 10 5 MCF7 cells on each well of a 6-well plate, a scratch was made by a micropipette yellow tip and the cells were washed and re-fed with serum-free medium. The Cells' images were taken before and after treatment period and were analyzed using ImageJ software. The area between two sides of each wound was measured for monitoring cell migration.
Statistical Analysis
The experimental data were analyzed by GraphPad Prism 6 and was provided as mean ± standard deviation (SD) of two independent experiments. The significance of differences between groups was analyzed by paired t-test. We considered p value less than 0.05 as significant, and p value less than 0.01 or 0.001 as highly significant.
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The DEGs of BC (all subtypes luminal A, luminal B, TN, Her2 + ) and DM2 were 2886 and 2299 respectively. After merging the data, a list of 196 co-regulated genes (156 upregulated and 40 downregulated) was obtained (Additional file 1).
The imported PPI network possessed 63 nodes and 60 edges. The resulted Degrees following topological characterization of PPI network were monitored and the top 12 nodes (20 percent of the whole nodes) were introduced as hubs (Table 1) .
The regulatory panel of co-regulated DEGs
The experimentally approved, mined and filtered TFs and miRNAs of identified hubs were visualized by Cytoscape 3.6.0 ( Fig. 1 ). The related biological processes (BP) were also revealed by GO analysis. The regulatory panel is available in Table 1 along the hubs' expressional status.
Biological processes used in our in vitro experiments
GO enrichment analysis held on co-regulated DEGs to introduce cellular concentration, function, and also redundant processes that can be targets of in-vitro experiments. Considering p value less than 0.05, the most important GO terms of molecular function and cellular component were IgG binding (GO:0019864) and Golgi apparatus (GO:0005794), respectively. The critical biological process was protein localization (GO:0008104). By analyzing the BP list, it was found that cell death and migration related processes were repeated so frequently that worth being analyzed under inhibiting treatments. The Fc gamma R-mediated phagocytosis was predicted to be the most enriched pathway between BC and DM2 (Table 2; for the complete list refer to Additional file 2).
Severe anti-proliferative effect of MTFN-CURC co-treatment on BC cell lines
dominant strategy MTFN adopts to stop cancer cell growth. We comprehended that co-treatment is more efficient against cancerous cells by inducing apoptosis (40.68%) more than single treatments.
Another way to ensure this finding is analyzing whether co-treatment alters apoptotic genes expression more than single treatments or not. As you see in Fig. 3B , both on electrophoresis gel and quantified chart, co-treatment significantly reduces expression of BCL2 as an anti-apoptotic gene and has slightly more effect on increasing expression of BAX as a pro-apoptotic gene. It also improves PTEN expression versus MTFN treated cells that is another proof for better effect of co-treatment in inducing anti-cancer effects because PTEN is a tumor suppressor.
Superior Effect of Co-treatment on Migration
Figure 4, demonstrates the pattern of BC cell migration in 24 h of being under the impact of applied drugs regarding the wound area. The result of these experiments showed that both single and co-treatments constrain cells' movement, but co-treatment is a little more efficient rather than single treatments.
Discussion
In the current study, we mapped the common regulatory factors behind two deadly human disorders BC and DM2 by analyzing microarray datasets, mining TFs, annotating miRNAs, and performing GO analysis. We introduced a regulatory panel containing 12 hubs and their related TFs and miRNAs as the most crucial factors responsible for the occurrence of these conditions.
The MTFN/CURC co-treatment exerted anti-proliferative effects, including both cell death and growth inhibition, on cancer cells that were manifested as slightly synergistic on MDA-MB-231
and additive on and MCF7 cell lines. The expression of BCL2 was decreased while that of BAX was increased under MTFN/CURC co-treatment compared to single treatments. Also, PTEN was overexpressed by co-treatment versus MTFN single treatment. Finally, the co-treatment promoted migration inhibition slightly more than single treatments did.
BC heterogeneity that drives tumorigenesis, metastasis, recurrence, and drug resistance necessitates drugs combinatory and multi-target strategies to be adopted for BC tumor cure. The gene expression profiling, regulatory genes, and pathways involved in this phenomenon need to be taken to account for ultimate solutions (39). Metabolic disorders like DM2 that result from desk-bound activities, also, are responsible for BC emergence and evolvement (40, 41) . In DM2, insulin resistance or scarcity of insulin production enhances glucose level in blood (42) and as a sign of BC-DM2 adjoining, the extra glucose will be consumed by cancerous cells as their fuel to survive and grow.
Our pathways analysis revealed FcγR-mediated phagocytosis as one of those pathways significantly shared between BC and DM2. The FcγR family is responsible for phagocytosis, activating macrophages, exuding reactive oxygen intermediates (ROIs), and having cytotoxic effect on tumors attached to antibodies (43). On one hand, FcγRI is directly involved in cancer immune antibody therapies that reduce tumor size including antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity (44, 45) . On the other hand, the monocytes of DM2 patients fail to properly promote FcγR-mediated phagocytosis, a problem that results in elevated blood glucose levels. This dysfunction shows direct correlations between DM2 and defected immune system (46). In line with the hubs' BP list that proposes distinct immune system processes, we propose that by targeting the identified immune biomarkers and pathways, the inflammatory cascades would be captured and the occurrence of both diseases would be decreased.
Mitochondrial dysfunction involved in intrinsic apoptotic pathways relevant to tumor formation contributes to development of both . We and others have reported reduced BCL2 expression and increased BAX expression by CURC and MTFN single treatments (50, 51) . Now, our current study reports that CURC-MTFN co-treatment more significantly induces BCL2 downregulation and BAX upregulation, hence inducing apoptosis more efficiently compared to single treatment. We found that MTFN adopts a strategy of inhibiting proliferation rather than inducing cell death. This may be due to MTFN ability to reduce circulating insulin leading to downregulation of proliferation pathways that are physiologically triggered by insulin or insulin growth factors (52). The findings were quantified by AnnexinV-FITC/PI double labeling in flow cytometry that confirmed MTFN proliferation inhibition and co-treatment cell death induction.
PTEN plays complex roles in multiple cellular processes including proliferation, survival, apoptosis, cell cycle regulation, adhesion, and migration (25, 53) . In our study, PTEN expression was reduced upon MTFN treatment but this reduction was compensated following MTFN/CURC co-treatment. Cell death induction by co-treatment suggests that the co-presence of MTFN and CURC may support the tumor-suppressing function of PTEN. Beside its anti-tumor activity, PTEN can also restrain Akt/PI3K pathway and so act as a negative regulator of proliferation (54). This restriction may downregulate or abate the insulin signaling pathway and result in insulin accumulation, insulin resistance, and hyperglycemia thereby co-promoting DM2 and BC.
Therefore, PTEN reduction can help in the optimal use of insulin in cells (55, 56). MTFN promotes PTEN down-regulation through AMPK dependent mode (52) and beside its anti-DM2 effects, controls BC indirectly via the Warburg effect. The AMPK pathway acts as a sensor of energy in cells and further plays a major role in insulin signaling (57-59).
Cell metastasis is a major complexity that makes cancer hard to control. Both MTFN and CURC have anti-metastatic effect on cancer cells (60, 61). The wound healing assay we carried out showed more efficient but insignificant differences in cell migration in our MTFN/CURC cotreated samples compared to single treatments. MTFN and CURC effects on angiogenesis genes that help the migration phenomenon are controversial and cell-dependent especially in BC (62-66). Therefore, further investigations are needed to monitor changes in the expression of specific genes in migration-related pathways so to understand the mechanisms associated with this cotreatment.
Conclusion
In conclusion, we produced bioinformatics data that were compatible with our experimental ones on MTFN/CURC co-treated BC cell lines. Our diverse experiments showed that the proposed cotreatment inhibitory strategy is more effective than single treatments. The xenografts' tumors derived from BC patients who also suffer DM2 provide suitable in vivo models for simultaneous evaluation of this co-treatment on both conditions. Also, the expression evaluation of involved factors in the introduced regulatory panel can be another phase of study to fully comprehend the underlying mechanisms.
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